172 related articles for article (PubMed ID: 36685039)
1. Recurrent visceral leishmaniasis relapses in HIV co-infected patients are characterized by less efficient immune responses and higher parasite load.
Takele Y; Mulaw T; Adem E; Womersley R; Kaforou M; Franssen SU; Levin M; Taylor GP; Müller I; Cotton JA; Kropf P
iScience; 2023 Feb; 26(2):105867. PubMed ID: 36685039
[TBL] [Abstract][Full Text] [Related]
2. Immunological factors, but not clinical features, predict visceral leishmaniasis relapse in patients co-infected with HIV.
Takele Y; Mulaw T; Adem E; Shaw CJ; Franssen SU; Womersley R; Kaforou M; Taylor GP; Levin M; Müller I; Cotton JA; Kropf P
Cell Rep Med; 2022 Jan; 3(1):100487. PubMed ID: 35106507
[TBL] [Abstract][Full Text] [Related]
3. Impaired Thymic Output Can Be Related to the Low Immune Reconstitution and T Cell Repertoire Disturbances in Relapsing Visceral Leishmaniasis Associated HIV/AIDS Patients.
Silva-Freitas ML; Corrêa-Castro G; Cota GF; Giacoia-Gripp C; Rabello A; Teixeira Dutra J; de Vasconcelos ZFM; Savino W; Da-Cruz AM; Santos-Oliveira JR
Front Immunol; 2020; 11():953. PubMed ID: 32508833
[No Abstract] [Full Text] [Related]
4. Visceral leishmaniasis as an independent cause of high immune activation, T-cell senescence, and lack of immune recovery in virologically suppressed HIV-1-coinfected patients.
Casado JL; Abad-Fernández M; Moreno S; Pérez-Elías MJ; Moreno A; Bernardino JI; Vallejo A
HIV Med; 2015 Apr; 16(4):240-8. PubMed ID: 25604328
[TBL] [Abstract][Full Text] [Related]
5. Multiple Relapses of Visceral Leishmaniasis in HIV Co-Infected Patients: A Case Series from Ethiopia.
Mohammed R; Fikre H; Schuster A; Mekonnen T; van Griensven J; Diro E
Curr Ther Res Clin Exp; 2020; 92():100583. PubMed ID: 32382359
[TBL] [Abstract][Full Text] [Related]
6. Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome.
ter Horst R; Collin SM; Ritmeijer K; Bogale A; Davidson RN
Clin Infect Dis; 2008 Jun; 46(11):1702-9. PubMed ID: 18419422
[TBL] [Abstract][Full Text] [Related]
7. Immune Activation and Bacterial Translocation: A Link between Impaired Immune Recovery and Frequent Visceral Leishmaniasis Relapses in HIV-Infected Patients.
Silva-Freitas ML; Cota GF; Machado-de-Assis TS; Giacoia-Gripp C; Rabello A; Da-Cruz AM; Santos-Oliveira JR
PLoS One; 2016; 11(12):e0167512. PubMed ID: 27907136
[TBL] [Abstract][Full Text] [Related]
8. Following successful anti-leishmanial treatment, neutrophil counts, CD10 expression and phagocytic capacity remain reduced in visceral leishmaniasis patients co-infected with HIV.
Takele Y; Adem E; Mulaw T; Müller I; Cotton JA; Kropf P
PLoS Negl Trop Dis; 2022 Aug; 16(8):e0010681. PubMed ID: 35969625
[TBL] [Abstract][Full Text] [Related]
9. The impact of highly active antiretroviral therapy (HAART) on visceral leishmaniasis in Spanish patients who are co-infected with HIV.
López-Vélez R
Ann Trop Med Parasitol; 2003 Oct; 97 Suppl 1():143-7. PubMed ID: 14678641
[TBL] [Abstract][Full Text] [Related]
10. Predictors of visceral leishmaniasis relapse in HIV-infected patients: a systematic review.
Cota GF; de Sousa MR; Rabello A
PLoS Negl Trop Dis; 2011 Jun; 5(6):e1153. PubMed ID: 21666786
[TBL] [Abstract][Full Text] [Related]
11. High levels of anti-Leishmania IgG3 and low CD4
Kuschnir RC; Pereira LS; Dutra MRT; de Paula L; Silva-Freitas ML; Corrêa-Castro G; da Costa Cruz Silva S; Cota G; Santos-Oliveira JR; Da-Cruz AM
BMC Infect Dis; 2021 Apr; 21(1):369. PubMed ID: 33874901
[TBL] [Abstract][Full Text] [Related]
12. Exploring prognosis in chronic relapsing visceral leishmaniasis among HIV-infected patients: Circulating Leishmania DNA.
Cota GF; de Sousa MR; de Assis TSM; Pinto BF; Rabello A
Acta Trop; 2017 Aug; 172():186-191. PubMed ID: 28501450
[TBL] [Abstract][Full Text] [Related]
13. Pre- & post-treatment evaluation of immunological features in Indian visceral leishmaniasis (VL) patients with HIV co-infection.
Sinha PK; Bimal S; Singh SK; Pandey K; Gangopadhyay DN; Bhattacharya SK
Indian J Med Res; 2006 Mar; 123(3):197-202. PubMed ID: 16778304
[TBL] [Abstract][Full Text] [Related]
14. Long term outcomes and prognostics of visceral leishmaniasis in HIV infected patients with use of pentamidine as secondary prophylaxis based on CD4 level: a prospective cohort study in Ethiopia.
Diro E; Edwards T; Ritmeijer K; Fikre H; Abongomera C; Kibret A; Bardonneau C; Soipei P; Mutinda B; Omollo R; van Griensven J; Zijlstra EE; Wasunna M; Alves F; Alvar J; Hailu A; Alexander N; Blesson S
PLoS Negl Trop Dis; 2019 Feb; 13(2):e0007132. PubMed ID: 30789910
[TBL] [Abstract][Full Text] [Related]
15. Visceral leishmaniasis and HIV co-infection in Bihar, India: long-term effectiveness and treatment outcomes with liposomal amphotericin B (AmBisome).
Burza S; Mahajan R; Sinha PK; van Griensven J; Pandey K; Lima MA; Sanz MG; Sunyoto T; Kumar S; Mitra G; Kumar R; Verma N; Das P
PLoS Negl Trop Dis; 2014 Aug; 8(8):e3053. PubMed ID: 25101665
[TBL] [Abstract][Full Text] [Related]
16. New world Leishmania spp. infection in people living with HIV: Concerns about relapses and secondary prophylaxis.
Araújo CF; Oliveira IBN; Silva MVT; Pereira LIA; Pinto SA; Silveira MB; Dorta ML; Fonseca SG; Gomes RS; Ribeiro-Dias F
Acta Trop; 2021 Dec; 224():106146. PubMed ID: 34562423
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 alters T helper cytokines, interleukin-12 and interleukin-18 responses to the protozoan parasite Leishmania donovani.
Wolday D; Berhe N; Britton S; Akuffo H
AIDS; 2000 May; 14(8):921-9. PubMed ID: 10853973
[TBL] [Abstract][Full Text] [Related]
18. Use of Pentamidine As Secondary Prophylaxis to Prevent Visceral Leishmaniasis Relapse in HIV Infected Patients, the First Twelve Months of a Prospective Cohort Study.
Diro E; Ritmeijer K; Boelaert M; Alves F; Mohammed R; Abongomera C; Ravinetto R; De Crop M; Fikre H; Adera C; Colebunders R; van Loen H; Menten J; Lynen L; Hailu A; van Griensven J
PLoS Negl Trop Dis; 2015; 9(10):e0004087. PubMed ID: 26431253
[TBL] [Abstract][Full Text] [Related]
19. Frequency of visceral leishmaniasis relapses in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy.
Mira JA; Corzo JE; Rivero A; Macias J; De Leon FL; Torre-Cisneros J; Gomez-Mateos J; Jurado R; Pineda JA
Am J Trop Med Hyg; 2004 Mar; 70(3):298-301. PubMed ID: 15031520
[TBL] [Abstract][Full Text] [Related]
20. The initial effectiveness of liposomal amphotericin B (AmBisome) and miltefosine combination for treatment of visceral leishmaniasis in HIV co-infected patients in Ethiopia: A retrospective cohort study.
Abongomera C; Diro E; de Lima Pereira A; Buyze J; Stille K; Ahmed F; van Griensven J; Ritmeijer K
PLoS Negl Trop Dis; 2018 May; 12(5):e0006527. PubMed ID: 29799869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
